Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372382 | 0.90 | TP53 (0.85) | PTPN11TP53ALDH1A1POLBKDM4E | |
| SCHEMBL2274512 | 0.88 | PTPN11 (1.00) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2278539 | 0.86 | PTPN11 (0.77) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2114376 | 0.85 | PTPN11 (1.00) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2274367 | 0.85 | PTPN11 (1.00) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2280039 | 0.82 | PTPN11 (1.00) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2279217 | 0.82 | PTPN11 (1.00) | PTPN11 | |
| SCHEMBL13536319 | 0.82 | PTPN11 (0.87) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL2273642 | 0.82 | PTPN11 (0.83) | PTPN11ALDH1A1POLBKDM4EPTPN7 | |
| SCHEMBL23217181 | 0.81 | PTPN11 (0.82) | PTPN11ALDH1A1POLBKDM4EPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010011666-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011666-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | PTPN1, PTPN2, PTPN7 | PTPN11 16/4885TP53 271/4885ALDH1A1 3494/4885 |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | PTPN11 16/4885TP53 124/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.